Icon Wealth Advisors LLC Buys New Shares in AstraZeneca PLC $AZNCF

Icon Wealth Advisors LLC bought a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 14,094 shares of the company’s stock, valued at approximately $2,473,000.

Other institutional investors have also recently bought and sold shares of the company. Hughes Financial Services LLC purchased a new stake in AstraZeneca in the fourth quarter valued at approximately $34,000. Mascoma Wealth Management LLC purchased a new stake in AstraZeneca in the fourth quarter valued at approximately $46,000. Triumph Capital Management purchased a new stake in AstraZeneca in the fourth quarter valued at approximately $75,000. Elyxium Wealth LLC purchased a new stake in AstraZeneca in the fourth quarter valued at approximately $102,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in AstraZeneca in the fourth quarter valued at approximately $122,000. 40.87% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Stock Performance

AstraZeneca stock opened at $187.10 on Friday. AstraZeneca PLC has a 1 year low of $122.26 and a 1 year high of $195.00. The firm has a 50 day moving average price of $187.10 and a 200 day moving average price of $185.98.

AstraZeneca Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.